Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
  • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/41—Porphyrin- or corrin-ring-containing peptides
  • A61K38/42—Haemoglobins; Myoglobins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
  • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds

Definitions

• This invention relates to a microparticles, in particular to self-assembled microparticles and their use as a component of an artificial blood product or a blood substitute and a method of preparing the microparticles.
• the microparticles and porous materials are useful in a wide range of physical and chemical processes especially where circulation in the blood stream is required.
• Blood surrogates also referred to as artificial blood, blood substitutes or oxygen carrying substitutes are of immense importance in circumstances where immediate blood supply is required but cannot be supplied through traditional blood transfusion. This can be for example in cases of haemophilia, in trauma units, in cases where blood can be contaminated by disease, during transplant surgery, or in remote locations away from medical facilities, for example on the battlefield and in road traffic accidents.
• a major purpose behind blood substitutes is the elimination of immune response, often seen in donor blood, and elimination of disease transmission.
• Religious objection to blood transfusion is also a limiting factor with donated blood.
• Blood substitutes can also be used for the storage and preservation of donor organs and other body tissues. It is also essential that the manufacturing process and cost of the ultimate substitute is cost effective.
• a 60g unit of donor blood typically costs a hospital $300 therefore the price of a blood substitute would need to be less than $5 per gram or provide a compelling reason for use.
• Investigation into development of viable blood substitutes has been ongoing for more than 70 years. The primary driver, the transport of oxygen by red blood cells has steered most research into the development of haemoglobin-based oxygen carriers (HBOCs).
• the chemical carrier of oxygen in haemoglobin is protoporphyrin IX which has more recently stimulated additional research into porphyrin based technologies.
• Microparticles as blood substitutes are known, for example as described in W09629346, WO2006108047 US-A-6,498,141 , HK1207560, US-A-5770727 US-A-5387672.
• Known blood substitutes suffer from a number of disadvantages. Some side effects reported include transient yellow skin discoloration, nausea, mild to moderate increase in blood pressure (10 to 20 mm/Hg), vomiting, low urine output, difficulty swallowing, flatulence, and low red blood cell count.
• Existing methodology for preparation of HBOCs suffers from complex manufacturing processes and result in polymers with broad ranges in size or heterogeneous polymeric forms of haemoglobin. The processes for manufacture often include complex organic chemistry, laborious dialysis and/or chromatographic separation technologies which are difficult to scale up.
• the current HBOCs in trials or development are often cross-linked with cytotoxic chemicals including, for example aldehydes such as giutaraidehyde where the mechanism of crosslinking is well known to be random, ill-defined and difficult to reproduce. It is postulated that dimeric forms of haemoglobin may be the cause of toxic effects in some HBOCs, however, the methods of cross-linking described in other HBOCs could be responsible for toxicity.
• haemoglobin can be cross-linked with bis-carboxy fatty acids.
• cross-linked haemoglobins disadvantageously have a broad molecular weight range and require complex and laborious purification processes including gel permeation, anion exchange and cation exchange chromatography to provide a usable product.
• the invention provides a blood substitute composition comprising mammalian haemoglobin and a self-assembled microparticle.
• the microparticle comprises an acid having two or more acid groups and an organic base which is soluble in a hydrophilic solvent.
• the blood substitute composition comprises a stable polymerized haemoglobin solution, comprising mammalian hemoglobin cross-linked with a self-assembled microparticle.
• blood-substitute denotes a HBOC composition for use in humans, mammals and other vertebrates.
• the HBOC is capable of transporting and transferring oxygen to vital organs and tissues.
• a vertebrate is defined to include humans, or any other vertebrate animals which uses blood in a circulatory system to transfer oxygen to tissue.
• a preferred vertebrate for treatment with the substance of this invention is a mammal, such as a primate, a canine, a feline, an equine, a porcine, a bovine, an ovine, a rodent or an avian.
• a vertebrate treated with the substance of this invention can be fetal, post-natal vertebrate, or a vertebrate at time of birth.
• the HBOC substance described herein may also be used for the storage and preservation of donor organs and mammalian tissues.
• microparticle enables a polymer of haemoglobin, of a regular size and shape and narrow molecular weight distribution to be produced.
• the microparticle contains natural materials, which are cross-linked by amide bonds and are therefore biodegradable by protease activity. As such, they are likely to be of little, or no concern to physiological functions.
• the present microparticles are advantageously monodispersed and small enough to travel through the smallest of capillaries where oxygen transfer occurs..
• the weight to weight ratio of the haemoglobin to cross-linking agent are significantly lower than hitherto known.
• Known products have a molecular weight in the range of 1 .7x10 7 .
• the present invention provides microparticles having a molecular weight of at least 1 .0x10 8 , preferably from 1.6x10 11 to 2x10 13 for example 4x10 12 .
• Haemoglobin from any suitable source may be used to prepare the blood substitute of the present invention. Examples include old or outdated human blood, bovine blood, ovine blood, porcine blood, equine blood, and blood from other vertebrates.
• Transgenic haemoglobin such as the transgenic haemoglobin described in EIO/TECHNOLOGY, 1z: 55-59 (1994) and recombinant haemoglobin (Nature, 356:258-60 (1992) can also be used.
• the microparticle acid suitably comprises a bis-acid, preferably a bis-aliphatic acid and suitably comprises two or more carboxylic acid groups, although other acid groups may be employed.
• the bis-acid is insoluble or sparingly soluble in the hydrophilic solvent.
• the acid preferably bis-aliphatic acid with an organic base which is soluble in the hydrophilic solvent, the acid may be solubilised.
• the solvent is suitably hydrophilic, preferably an aqueous solution, for example a water in oil emulsion within an aqueous phase, and especially water.
• an aqueous-based solvent preferably water, allows the microparticle to be used in applications in which environmental considerations are important.
• the microparticle may be formulated into an aqueous-based product which may be suitable for personal use or consumption, medical uses and for example as a biocide.
• the bis-aliphatic acid comprises a bis-carboxylic fatty acid in which terminal carboxylic acids are linked by a region which is less hydrophilic than the terminal carboxylic acids and is preferably hydrophobic.
• the less hydrophilic region may comprise a backbone with substituents and/or the backbone may comprise heteroatoms, for example poly-epsilon lysine.
• the region linking the carboxylic acids is hydrophobic and preferably a hydrocarbyl group.
• the hydrophobic group is an aliphatic hydrocarbyl group.
• the bis-acid comprises a compound of general formula HOOC-(CH 2 ) n -COOH wherein n is sufficiently large that the bis acid is sparingly soluble or insoluble in water.
• n is at least 5, more preferably at least 6, especially at least 7.
• n is not more than 40, preferably not more than 36, more preferably not more than 25, and especially not more than 20.
• n is from 7 to 18.
• the organic acid comprises a C 7 to Ci 8 bis carboxylic fatty acid.
• the organic acid comprises a C 7 to Ci 3 bis carboxylic fatty acid together with a further acid selected from a EDTA, nitrolotriacetic acid and a monocarboxylic acid, preferably a C 6 to Ci 8 carboxylic acid, for example caproic acid, palmitic acid and octanoic acid.
• a further acid selected from a EDTA, nitrolotriacetic acid and a monocarboxylic acid, preferably a C 6 to Ci 8 carboxylic acid, for example caproic acid, palmitic acid and octanoic acid.
• the size of the microparticle may be tailored. A longer hydrophobic portion connecting the acid groups suitably provides a larger microparticle. For example where n is 8, sebacic acid, a particle of size 2,6 microns may be obtained and where n is 1 1 , brassylic acid, a particle of size 3,0 micron
• the bis-carboxy fatty acid can also be unsaturated for example traumatic acid, or substituted or both unsaturated and substituted.
• the substitution does not cause the bis-acid to be soluble in aqueous solution.
• the bis-aliphatic acid may comprise: a bis-phosphonic acid of general formula (HO) 2 OP- (CH 2 )n-PO(OH) 2 or an unsaturated bis-phosphonic acid; a mono-carboxylic mono- phosphonic acid of general formula HOOC-(CH 2 )n-PO(OH) 2 or an unsaturated version of such bis-acid; a bis-sulfonic acid of general formula (HO)0 2 S-(CH 2 ) n -S0 2 (OH) or an unsaturated version of such bis-acid; a mono-carboxylic mono-sulfonic acid of general formula HOOC-(CH 2 ) n -S0 2 (OH) or an unsaturated version of such a bis-acid; a bis- boronic acid of general formula (HO) 2 B-(CH 2 ) n -B(OI-l) 2 or an unsaturated bis-boronic acid, or substituted bis-boronic acid; a mono-car
• n is not more than 40, preferably not more than 36 more preferably not more than 25, and especially not more than 20.
• n is from
• the organic base combines with the bis-acid moieties such that the combination of the two components comprises two separate hydrophilic or ionic head regions connected by a hydrophobic region.
• the hydrophobic regions and hydrophilic regions of adjacent bis-acids with organic base align to form micelles and lead to self-assembly of the microparticles of the invention.
• the microparticle comprises a multi-lamellar structure in which further molecules comprising the bis-acids with the organic base, align with the hydrophilic head of another bis-acid/organic base so as to form a multi-lamellar structure.
• the organic base may be selected from a range of bases which, together with the bis- acid forms a self-assembling microparticle.
• the organic base comprises an amine, suitably an aliphatic amine or an aromatic amine having a basic character or other nitrogen-containing base.
• suitable organic bases include alkylated amines and polyamines including amines having one or two Ci -4 N-alkyl -groups, for example methylated amines.
• Examples of preferred amines include N- methylmorpholine, 4-methylmorpholine (NMM), ⁇ , ⁇ -dimethylaminoethanol (DMAE), 4- dimethylaminopyridine (DMAP), imidazole or 1 -methylamidazole, poly(diallyldimethylammonium chloride) (PDAC), didecyldimethylammonium chloride (DDAC) and dodecyldipropylenetriamine (DDPT).
• NMM 4-methylmorpholine
• DMAE ⁇ , ⁇ -dimethylaminoethanol
• DMAP 4- dimethylaminopyridine
• imidazole or 1 -methylamidazole imidazole or 1 -methylamidazole
• PDAC poly(diallyldimethylammonium chloride)
• DDAC didecyldimethylammonium chloride
• DDPT dodecyldipropylenetriamine
• the acid is suitably one or more of brassylic acid, sebacic acid and azelaic acid in combination with a base selected from methylmorpholine (NMM), ⁇ , ⁇ -dimethylaminoethanol (DMAE), 4-dimethylaminopyridine (DMAP), imidazole, 1 - methylamidazole, poly(diallyldimethylammonium chloride) (PDAC), didecyldimethylammonium chloride (DDAC) and dodecyldipropylenetriamine (DDPT).
• a base selected from methylmorpholine (NMM), ⁇ , ⁇ -dimethylaminoethanol (DMAE), 4-dimethylaminopyridine (DMAP), imidazole, 1 - methylamidazole, poly(diallyldimethylammonium chloride) (PDAC), didecyldimethylammonium chloride (DDAC) and dodecyldipropylenetriamine (DDPT).
• Preferred examples include microparticles comprising brassylic acid and PDAC, brassylic acid and DDAC, brassylic acid and DDPT, sebacic acid and NMM, poly epsilon lysine in combination with one or more of sebacic acid, brassylic acid and azelaic acid.
• microparticles according to the invention comprising amines having antimicrobial properties are particularly suited for use as antimicrobial compositions and biocides.
• the level of antimicrobial activity of the base may be higher when in the form of a self-assembled microparticle according to the invention as compared to when in a conventional formulation.
• the invention also provides the use of a self-assembled microparticle comprising a bis acid and a water-soluble base, the base being displaceable by a protein and for covalent cross-linking.
• the invention provides a self-assembled microparticle comprising an acid having two or more acid groups, preferably a bis acid, covalently bonded to a haemoglobin molecule.
• the covalently bonded haemoglobin is suitably produced by adding haemoglobin to a self-assembled microparticle comprising an acid having two or more acid groups and a water-soluble base which is displaceable in part or whole by haemoglobin.
• the protein suitably comprises haemoglobin either individually or in combination with one or more other proteins, for example a catalase and a superoxide dismutase.
• the acid and base are suitably combined in relative quantities such that the molar ratio of acid groups in the acid to basic groups in the base is approximately stoichiometriuc such that self-assembled microparticles form.
• the molar quantity of acid groups to base groups may be less or more than stoichiometric provided the self-assembled particles form. Where the ratio of acid groups to base groups is too low or too high, -assembled particles do not form as the excess component disrupts structure of the acid and base.
• the ratio of acid groups to basic groups that allow formation of the self-assembled particle will vary depending on the particular acid and particular base. The skilled person will be able to determine whether a self-assembled particle is formed by observing under a microscope with magnification at a level to visually observe particles for example at 40x magnification. The relative quantities of the acid and base will be able to be modified to determine the minimum and maximum ratio of the components at which microparticles form. Acids having longer chains may provide microparticles which are more stable than microparticles (with the same base and same molar ratio) comprising an acid having a shorter chain. The greater stability may allow a lower level of acid to be employed and a lower ratio of acid groups to basic groups may still allow a microparticle to form.
• the ratio of acid groups to basic groups in the acid and base is from 0.6 to 1 .4:1 , preferably 0.7 to 1 .3:1 , more preferably 0.8 to 1 .2:1 and desirably 0.9 to 1.1 :1.
• Sebacic acid and brassylic acid are examples of preferred acids.
• a microparticle comprising sebacic acid with a base has a ratio of sebacic acid to base of 0.85 to 1.15:1 .
• a microparticle comprising brassylic acid with a base has a ratio of brassylic acid to base of 0.8 to 1 .2:1.
• the acid and base are present at levels to provide a molar ratio of acid groups to basic groups of 1 :1.
• the organic base may be reactive so as to enable cross-linking of the self-assembled microparticles for form a macroporous material.
• the organic base need not be reactive in which case it may suitably be displaced by another reactive species to allow subsequent cross-linking to form a macroporous material.
• the solvent soluble organic base can be displaced by addition of a reactive species including, but not limited to, amine containing organic components.
• the amine suitably allows cross-linking of the microparticles by amide bond formation.
• the amine containing organic component is a polymeric amine including but not limited to a peptide, protein, polyallylamine, polyethyleneimine and other polyamines.
• Suitable amines and polyamines include ethylenediamine, poly-e-lysine, polyallylamine, polyethyleneimine, aminopropyltrialkoxysilanes, 3-(2- aminoethylamino)propyltrimethoxysilane, N-(3-(trimethoxysilyl)-propyl)diethyenetriamine.
• the above aforementioned bis acids may be mixed in any proportions.
• the reactive amines may also be mixed.
• the microparticles comprise functional components, tailored according to the intended use.
• a self-assembled microparticle or macroporous material according to the invention may also comprise a functional material supported by the polymer.
• suitable functional materials include a catalyst, an initiator species for peptide synthesis or oligonucleotide synthesis, a pharmaceutical active, an agrochemical active, a macromolecule, an enzyme, a nucleic acid sequence and a protein.
• the invention is particularly useful in supporting precious metal catalysts, for example palladium catalysts. A particular advantageous example is palladium.
• the self-assembled microparticle may be produced by a method comprising contacting the acid having two or more acid groups with an organic base in an aqueous medium, preferably water.
• the polymerisation and cross-linking is initiated by processes known to those skilled in the art.
• self-assembled microparticles prepared in water with an amine containing component can be cross-linked using a water soluble carbodiimide.
• the self-assembled microparticle material according to the invention is substantially mono-disperse. That is the material has particles which are all substantially the same size.
• Monodisperse microparticles may advantageously travel in the blood stream without transferring across capillary walls or blocking capillaries, effectively behaving in a similar manner to an erythrocyte.
• the self-assembled microparticles of the present invention may be used in separate or combined processes, for example, drug delivery in combination with oxygen transport.
• the self-assembled microparticles may be used as a carrier to carry a compound which is to be released over a period of time, for example a pharmaceutical.
• This use provides a means of tailoring a dosage regime of the compound according to the loading of the compound in the support. In the case of a pharmaceutical, this may be advantageous in assisting the correct dosage of an active, for example with continuous slow release rather than requiring a patient to take periodic large doses.
• microparticles of the invention may be formulated into a composition for a wide- range of variations in use, including a composition containing haemoglobin in combination with other proteins or enzymes such as a catalase, or in combination with compounds that provide and allosteric effect such as 2,3-bisphosphoglyceric acid
• Example 1 Preparation of self-assembled microparticles
• PDAC 16.167g of 20% solution, 20mmol
• water 100cm 3
• NaOH 0.8g, 20mmol
• Brassylic acid (2.44g, l Ommol) was added to this solution and allowed to dissolve.
• Human haemoglobin (2.44g) was dissolved in water (100cm 3 ) and added to the solution of brassylic acid/PDAC SpheriSomes. The mixture was filtered through a 0.5 ⁇ cartridge and a sample placed on a microscope. Microspheres of ⁇ 3 ⁇ diameter were still present.
• PDAC (16.167g of 20% solution, 20mmol) was dissolved in water (100cm 3 ) and NaOH (0.8g, 20mmol) added. Brassylic acid (2.44g, l Ommol) was added to this solution and allowed to dissolve. Human haemoglobin (3.66g) was dissolved in water (100cm 3 ) and added to the solution of brassylic acid/PDAC SpheriSomes. The mixture was filtered through a 0.5 ⁇ cartridge and a sample placed on a microscope. Microspheres of ⁇ 3 ⁇ diameter were still present. A solution of EDCI (4.6g, 24mmol) and HOBt (0.47g,1.2mmol) were dissolved in water (50cm 3 ) and added to the above solution.
• PDAC (16.167g of 20% solution, 20mmol) was dissolved in water (100cm 3 ) and NaOH (0.8g, 20mmol) added. Brassylic acid (2.44g, l Ommol) was added to this solution and allowed to dissolve. Human haemoglobin (4.88g) was dissolved in water (100cm 3 ) and added to the solution of brassylic acid/PDAC SpheriSomes. The mixture was filtered through a 0.5 ⁇ cartridge and a sample placed on a microscope. Microspheres of ⁇ 3 ⁇ diameter were still present. A solution of EDCI (4.6g, 24mmol) and HOBt (0.47g,1.2mmol) were dissolved in water (50cm 3 ) and added to the above solution.
• L-Carnitine (1 .612g, l Ommol) was suspended in water (20cm 3 ) and NaOH (0.4g, l Ommol) added.
• Brassylic acid (1 .22g, 5mmol) was added to this solution and the mixture allowed to dissolve.
• Human haemoglobin (1 .83g) was dissolved in water (200cm 3 ) and added to the solution of Brassylic acid/carnitine SpheriSomes. The mixture was filtered through a 0.5 ⁇ cartridge and a sample placed on a microscope. Microspheres of ⁇ 3 ⁇ diameter were present.
• Tetraethyl ammonium hydroxide (TEA.OH) (4.2cm 3 of a 35% solution, l Ommol) was added to water (20cm 3 ) and Brassylic acid (1 .22g, 5mmol) was added to this solution. The Brassylic acid dissolved immediately to form SpheriSomes. Human haemoglobin (1 .83g) was dissolved in water (200cm 3 ) and added to the solution of Brassylic acid/TEA.OH SpheriSomes. The mixture was filtered through a 0.5 ⁇ cartridge and a sample placed on a microscope. Microspheres of ⁇ 3 ⁇ diameter were still present.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Dispersion Chemistry (AREA)
• Hematology (AREA)
• Dermatology (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=57140038

Family Applications (1)

Country Status (6)

Cited By (1)

Family Cites Families (10)

• 2016
  • 2016-09-05 GB GBGB1615050.0A patent/GB201615050D0/en not_active Ceased
• 2017
  • 2017-09-05 JP JP2019533688A patent/JP7123935B2/ja active Active
  • 2017-09-05 WO PCT/EP2017/072270 patent/WO2018042059A1/en not_active Ceased
  • 2017-09-05 US US16/330,184 patent/US10471130B2/en active Active
  • 2017-09-05 EP EP17768043.6A patent/EP3506887A1/en active Pending
  • 2017-09-05 GB GB1714257.1A patent/GB2558976B/en active Active
• 2019
  • 2019-04-04 ZA ZA2019/02128A patent/ZA201902128B/en unknown
  • 2019-10-02 US US16/590,854 patent/US11273207B2/en active Active

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events